| __timestamp | Neurocrine Biosciences, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 570979 |
| Thursday, January 1, 2015 | 33800000 | 2185000 |
| Friday, January 1, 2016 | 35900000 | 4554000 |
| Sunday, January 1, 2017 | 1254000 | 3605000 |
| Monday, January 1, 2018 | 4889000 | 5527000 |
| Tuesday, January 1, 2019 | 7400000 | 5234000 |
| Wednesday, January 1, 2020 | 10100000 | 6126000 |
| Friday, January 1, 2021 | 14300000 | 6784000 |
| Saturday, January 1, 2022 | 23200000 | 7592000 |
| Sunday, January 1, 2023 | 39700000 | 11450000 |
| Monday, January 1, 2024 | 34000000 |
Unleashing the power of data
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the cost of revenue for two prominent companies: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc., from 2014 to 2023. Over this period, Neurocrine Biosciences has seen a significant increase in its cost of revenue, peaking at nearly 40 million in 2023, a remarkable 176% rise from 2014. In contrast, Travere Therapeutics experienced a more modest growth, with its cost of revenue increasing by approximately 1900% over the same period, reaching 11.45 million in 2023. These trends highlight the varying financial strategies and market conditions faced by these companies. As the biotech industry continues to evolve, monitoring such financial metrics will be key to understanding the broader market dynamics.
Cost of Revenue Comparison: AbbVie Inc. vs Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: Zoetis Inc. vs Travere Therapeutics, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Travere Therapeutics, Inc.
BeiGene, Ltd. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Telix Pharmaceuticals Limited
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Lantheus Holdings, Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cytokinetics, Incorporated vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: CRISPR Therapeutics AG vs Travere Therapeutics, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Travere Therapeutics, Inc.'s Expenses